Aerie Pharmaceuticals (AERI) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	AERI
Entity Registrant Name	AERIE PHARMACEUTICALS INC
Entity Central Index Key	1337553
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		25,423,486

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$113,450	$85,586
Short-term investments	56,286	54,339
Prepaid expenses and other current assets	1,219	1,122
Total current assets	170,955	141,047
Long-term investments	9,574	18,275
Furniture, fixtures and equipment, net	796	240
Other assets, net	13,872	1,523
Total assets	195,197	161,085
Current liabilities
Accounts payable and other current liabilities	21,852	8,336
Interest payable	539	551
Total current liabilities	22,391	8,887
Convertible notes, net of discounts	124,187	124,156
Total liabilities	146,578	133,043
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred stock, $0.001 par value; 15,000,000 shares authorized as of March 31, 2015 and December 31, 2014; None issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2015 and December 31, 2014; 25,275,672 and 24,018,577 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	25	24
Additional paid-in capital	209,092	171,326
Accumulated other comprehensive loss	-58	-107
Accumulated deficit	-160,440	-143,201
Total stockholders’ equity	48,619	28,042
Total liabilities and stockholders’ equity	$195,197	$161,085

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	25,275,672	24,018,577
Common stock, shares outstanding	25,275,672	24,018,577

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating expenses
General and administrative	($8,023)	($3,612)
Research and development	-11,618	-5,370
Loss from operations	-19,641	-8,982
Other income (expense), net	2,402	2,311
Net loss	-17,239	-6,671
Net loss attributable to common stockholders—basic and diluted	-17,239	-6,671
Net loss per share attributable to common stockholders—basic and diluted	($0.70)	($0.28)
Weighted average number of common shares outstanding—basic and diluted	24,602,668	23,717,393
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	49	-21
Comprehensive loss	($17,190)	($6,692)

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
Interest Paid	$551	$0
Cash flows from operating activities
Net loss	-17,239	-6,671
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	24	15
Amortization of deferred financing costs and debt discount	77	0
Amortization of discount on available-for-sale investments	163	56
Stock-based compensation	2,741	1,922
Changes in operating assets and liabilities
Prepaid, current and other assets	-205	-27
Accounts payable and other current liabilities	1,144	208
Interest payable	-12	0
Net cash used in operating activities	-13,307	-4,497
Cash flows from investing activities
Purchase of available-for-sale investments	-8,188	-29,345
Maturity of available-for-sale investments	14,828	0
Purchase of furniture, fixtures and equipment	-539	-29
Net cash provided by (used in) investing activities	6,101	-29,374
Cash flows from financing activities
Proceeds from sale of common stock	35,000	0
Proceeds from exercise of stock purchase rights	70	65
Net cash provided by financing activities	35,070	65
Net change in cash and cash equivalents	27,864	-33,806
Beginning of period	85,586	69,649
End of period	$113,450	$35,843

The_Company

The Company	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
The Company	The Company
	Aerie Pharmaceuticals, Inc. (“Aerie”), with its wholly-owned subsidiary Aerie Pharmaceuticals Limited (“Aerie Limited” and, together with Aerie, the “Company”), is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of topical, small molecule products to treat patients with glaucoma and other diseases of the eye. The Company has its principal executive offices in Irvine, California and operates as one business segment.
	The Company has not yet commenced primary operations or generated product revenue. The Company’s activities since inception primarily consisted of developing product candidates, raising capital and performing research and development activities. The Company has no current source of revenue to sustain its present activities, and it does not expect to generate revenue until and unless it receives regulatory approval of and successfully commercializes its product candidates. The Company has incurred losses and experienced negative operating cash flows since inception.
	The Company has funded its operations primarily through the sale of equity securities and issuance of convertible notes. In October 2013, the Company completed its initial public offering (“IPO”) and issued 7,728,000 shares of its common stock at an IPO price of $10.00 per share, including 1,008,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. The Company received net proceeds from the IPO of approximately $68.3 million, after deducting underwriting discounts and commissions of $5.4 million and expenses of $3.6 million. On September 30, 2014, the Company issued $125.0 million aggregate principal amount of senior secured convertible notes (the “2014 Convertible Notes”). The Company received net proceeds from the issuance of the 2014 Convertible Notes of approximately $124.1 million, after deducting discounts and certain expenses of $875,000. Refer to Note 8 for further information regarding the 2014 Convertible Notes.
	On November 3, 2014, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on November 10, 2014. The shelf registration statement permits: (i) the offering, issuance and sale of up to a maximum aggregate offering price of $150.0 million of the Company’s common stock; (ii) sales of common stock by certain selling stockholders; and (iii) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under an “at-the-market” sales agreement with Cantor Fitzgerald & Co. The common stock that may be offered, issued and sold by the Company under the “at-the-market” sales agreement is included in the $150.0 million of common stock that may be offered, issued and sold by the Company under the shelf registration statement. As of and for the three months ended March 31, 2015, the Company issued and sold 1,204,248 shares of its common stock under the “at-the-market” sales agreement. The Company received net proceeds of approximately $35.0 million, after deducting commissions of approximately $1.0 million.
	In March 2015, the Company more closely aligned its corporate structure with the strategy of developing its business outside of North America by establishing Aerie Limited, a wholly-owned subsidiary organized under the laws of the Cayman Islands. In addition, Aerie assigned the beneficial rights to its non-U.S. and Canadian intellectual property to Aerie Limited (the “IP Assignment”). As part of the IP Assignment, Aerie and Aerie Limited entered into a research and development agreement and cost sharing agreement pursuant to which Aerie and Aerie Limited will share the costs of the development of intellectual property. Refer to Note 9 for a description of the tax impact of the IP Assignment.
	If the Company does not successfully commercialize any of its product candidates, it may be unable to generate product revenue or achieve profitability. Accordingly, the Company may be required to obtain further funding through other public or private offerings, debt financing, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or commercialization efforts. The Company estimates that it has sufficient funding to sustain operations through product commercialization of Rhopressa™ and Roclatan™, pending successful outcome of their clinical trials and U.S. Food and Drug Administration (“FDA”) approval.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies
	Basis of Presentation
	The Company’s interim consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
	Principles of Consolidation
	The interim consolidated financial statements include the accounts of Aerie and its wholly-owned subsidiary. All intercompany accounts, transactions and profits have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the valuation of stock options and operating expense accruals. Actual results could differ from these estimates.
	Investments
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase. The Company’s investments are comprised of certificates of deposit, commercial paper, corporate bonds and government agency securities that are classified as available-for-sale in accordance with ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year.
	Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in Accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of Other income (expense), net (Note 3). There were no realized gains or losses recognized for the three months ended March 31, 2015 or 2014.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to period end. As of March 31, 2015, there were no investments with a fair value that was significantly lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period.
	Deferred Financing Costs
	Deferred financing costs consist of financing costs incurred by the Company in connection with the closing of Aerie’s 2014 Convertible Notes and are included in Other assets. The Company amortizes deferred financing costs through the earlier of maturity or the conversion of the 2014 Convertible Notes using the effective interest method. Refer to Note 8 for further information regarding the 2014 Convertible Notes.
	Fair Value Measurements
	The Company records certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The fair value of the Company’s financial instruments, including cash and cash equivalents, short-term investments, other current assets, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of these instruments. The carrying amounts of long-term investments represent their estimated fair values. The estimated fair value of Aerie’s 2014 Convertible Notes was $174.0 million and $163.8 million as of March 31, 2015 and December 31, 2014, respectively. As of March 31, 2015 and December 31, 2014, all outstanding warrants are classified as equity and are recorded within additional paid-in capital on the consolidated balance sheets.
	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU 2015-03, which simplifies the presentation of debt issuance costs. The new standard is effective for the Company for interim and annual periods beginning after December 15, 2015, with early adoption permitted. Upon adoption of ASU 2015-03, the Company will present debt issuance costs as a direct reduction to the debt liability rather than as an asset on its consolidated balance sheets.
	In August 2014, the FASB issued ASU 2014-15, which provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for the Company for the annual period ending after December 15, 2016 and for annual and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on the Company’s consolidated financial statements.
	Net Loss per Share Attributable to Common Stock
	Basic net loss per share attributable to common stock (“Basic EPS”) is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities with the exception of warrants for common stock with a $0.05 exercise price, which are exercisable for nominal consideration and are therefore included in the calculation of the weighted-average number of shares of common stock as common stock equivalents. Diluted net loss per share attributable to common stock (“Diluted EPS”) gives effect to all dilutive potential shares of common stock outstanding during this period. For Diluted EPS, net loss attributable to common stockholders used in calculating Basic EPS is adjusted for certain items related to the dilutive securities.
	For all periods presented, the Company’s potential common stock equivalents have been excluded from the computation of Diluted EPS as their inclusion would have the effect of reducing the net loss per share of common stock. Therefore, the denominator used to calculate Basic EPS and Diluted EPS is the same in all periods presented.
	The Company’s potential common stock equivalents that have been excluded from the computation of Diluted EPS for all periods presented consist of the following:
		THREE MONTHS ENDED MARCH 31,
		2015	2014
	2014 Convertible Notes(1)	5,040,323	—
	Outstanding stock options	4,548,860	4,177,660
	Stock purchase warrants	309,506	309,506
	Unvested restricted common stock awards	156,143	210,317
	-1	Conversion is limited to a 9.985% ownership cap in shares of common stock by the holder. Additionally, the 2014 Convertible Notes provide for an increase in the conversion rate if conversion is elected in connection with a significant corporate transaction. Refer to Note 8 for further information regarding the 2014 Convertible Notes.

Other_Income_Expense_Net

Other Income (Expense), Net	3 Months Ended
	Mar. 31, 2015
Other Income and Expenses [Abstract]
Other Income, Net	Other Income (Expense), Net
	Other income (expense), net consists of the following:
		THREE MONTHS ENDED
		MARCH 31,
	(in thousands)	2015			2014
	Interest and amortization expense	$	(617	)	$	—
	Sale of New Jersey state tax benefit	2,898			2,288
	Investment and other income, net	121			23
		$	2,402		$	2,311

Investments

Investments	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments	Investments
	Cash, cash equivalents and investments as of March 31, 2015 included the following:
	(in thousands)	AMORTIZED		GROSS		GROSS			FAIR
		COST		UNREALIZED		UNREALIZED			VALUE
				GAINS		LOSSES
	Cash and cash equivalents:
	Cash and money market accounts	$	113,450	$	—	$	—		$	113,450
	Total cash and cash equivalents	$	113,450	$	—	$	—		$	113,450
	Investments:
	Certificates of deposit (due within 1 year)	$	23,859	$	2	$	(6	)	$	23,855
	Certificates of deposit (due within 2 years)	5,389		2		—			5,391
	Commercial paper (due within 1 year)	5,993		1		(1		)	5,993
	Corporate bonds (due within 1 year)	20,422		—		(37		)	20,385
	Corporate bonds (due within 2 years)	4,198		—		(15		)	4,183
	Government agencies (due within 1 year)	6,056		—		(3		)	6,053
	Total investments	$	65,917	$	5	$	(62	)	$	65,860
	Total cash, cash equivalents, and investments	$	179,367	$	5	$	(62	)	$	179,310
	Cash, cash equivalents and investments as of December 31, 2014 included the following:
	(in thousands)	AMORTIZED		GROSS		GROSS			FAIR
		COST		UNREALIZED		UNREALIZED			VALUE
				GAINS		LOSSES
	Cash and cash equivalents:
	Cash and money market accounts	$	84,613	$	—	$	—		$	84,613
	Certificates of deposit	472		—		—			472
	Corporate bonds	501		—		—			501
	Total cash and cash equivalents	$	85,586	$	—	$	—		$	85,586
	Investments:
	Certificates of deposit (due within 1 year)	$	25,823	$	—	$	(9	)	$	25,814
	Certificates of deposit (due within 2 years)	4,429		1		(3		)	4,427
	Commercial paper (due within 1 year)	5,988		1		(3		)	5,986
	Corporate bonds (due within 1 year)	16,487		—		(24		)	16,463
	Corporate bonds (due within 2 years)	13,912		—		(64		)	13,848
	Government agencies (due within 1 year)	6,082		—		(6		)	6,076
	Total investments	$	72,721	$	2	$	(109	)	$	72,614
	Total cash, cash equivalents, and investments	$	158,307	$	2	$	(109	)	$	158,200

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820 on fair value measurements. As defined in the guidance, fair value, defined as an exit price, represents the amount that would be received to sell an asset or pay to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering these assumptions, the guidance defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value.
	•	Level 1—Unadjusted quoted prices in active, accessible markets for identical assets or liabilities.
	•	Level 2—Other inputs that are directly or indirectly observable in the marketplace.
	•	Level 3—Unobservable inputs that are supported by little or no market activity.
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The following tables summarize the fair value of financial assets and liabilities that are measured at fair value and the classification by level of input within the fair value hierarchy:
		FAIR VALUE MEASUREMENTS AS OF
		31-Mar-15
	(in thousands)	Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
	Cash and money market accounts	$	113,450	$	—	$	—	$	113,450
	Total cash and cash equivalents	$	113,450	$	—	$	—	$	113,450
	Investments:
	Certificates of deposit	$	—	$	29,246	$	—	$	29,246
	Commercial paper	—		5,993		—		5,993
	Corporate bonds	—		24,568		—		24,568
	Government agencies	—		6,053		—		6,053
	Total investments	$	—	$	65,860	$	—	$	65,860
	Total cash, cash equivalents, and investments	$	113,450	$	65,860	$	—	$	179,310
		FAIR VALUE MEASUREMENTS AS OF
		31-Dec-14
	(in thousands)	Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
	Cash and money market accounts	$	84,613	$	—	$	—	$	84,613
	Certificates of deposit	—		472		—		472
	Corporate bonds	—		501		—		501
	Total cash and cash equivalents	$	84,613	$	973	$	—	$	85,586
	Investments:
	Certificates of deposit	$	—	$	30,241	$	—	$	30,241
	Commercial paper	—		5,986		—		5,986
	Corporate bonds	—		30,311		—		30,311
	Government agencies	—		6,076		—		6,076
	Total investments	$	—	$	72,614	$	—	$	72,614
	Total cash, cash equivalents, and investments	$	84,613	$	73,587	$	—	$	158,200
	As of March 31, 2015 and December 31, 2014, the estimated fair value of Aerie’s 2014 Convertible Notes was $174.0 million and $163.8 million, respectively. The estimated fair value of the 2014 Convertible Notes was determined using a scenario analysis and Monte Carlo simulation model to capture the various features of the 2014 Convertible Notes. The scenario analysis and Monte Carlo simulation require the use of Level 3 unobservable inputs and subjective assumptions, including but not limited to the probability of conversion, stock price volatility, the risk free interest rate and credit spread. The estimates presented are not necessarily indicative of amounts that could be realized in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.

Other_Assets_Net

Other Assets, Net	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets, Net	Other Assets, Net
	Other assets, net consists of the following:
	(in thousands)	31-Mar-15		DECEMBER 31, 2014
	Deferred financing costs	$	1,378	$	1,479
	Prepaid taxes(1)	12,341		—
	Miscellaneous	153		44
		$	13,872	$	1,523
	-1	Under ASC 810, Consolidation, the income tax expense resulting from the IP Assignment of $12.3 million for the three months ended March 31, 2015 was recorded as a prepaid asset. The prepaid asset is expected to be substantially offset by current year losses and amortized ratably over the estimated remaining patent life of the intellectual property subject to the IP Assignment, through approximately 2030. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Accounts_Payable_Other_Current

Accounts Payable & Other Current Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable & Other Current Liabilities	Accounts Payable & Other Current Liabilities
	Accounts payable and other current liabilities consist of the following:
	(in thousands)	31-Mar-15		DECEMBER 31,
				2014
	Accounts payable	$	3,180	$	2,068
	Accrued expenses and other liabilities:
	Employee benefits and compensation related accruals(1)	940		2,257
	General and administrative related accruals	1,252		731
	Research and development related accruals	4,149		3,280
	Accrued income taxes(2)	12,331		—
		$	21,852	$	8,336
	-1	Comprised of accrued bonus, accrued vacation, and liabilities under the Company’s employee stock purchase plan.
	-2	Accrued income taxes are the result of the tax gain from the IP Assignment and are expected to be substantially offset by current year losses. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Convertible_Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes
	On September 30, 2014, Aerie issued the 2014 Convertible Notes to Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. (collectively, “Deerfield”). On January 1, 2015, Deerfield Special Situations International Master Fund, L.P. transferred all of its rights under the 2014 Convertible Notes to Deerfield Special Situations Fund, L.P.
	The 2014 Convertible Notes bear interest at a rate of 1.75% per annum payable quarterly in arrears on the first business day of each January, April, July and October. The 2014 Convertible Notes mature on the seventh anniversary from the date of issuance, unless earlier converted.
	The 2014 Convertible Notes constitute a senior secured obligation of Aerie, collateralized by a first priority security interest in substantially all of the assets of Aerie. The 2014 Convertible Notes provide that, upon the request of Aerie, Deerfield will release all of the liens on the collateral if both of the following occur: (i) beginning one month after FDA approval of either Rhopressa™ or Roclatan™, shares of Aerie’s common stock have traded at a price above $30 per share (subject to adjustment for any subdivision or combination of outstanding common stock) for 30 consecutive trading days, and (ii) Aerie is prepared to close a financing that will be secured by a lien on Aerie’s assets, subject only to the release of the lien on the Aerie’s assets by Deerfield.
	In connection with the IP Assignment, Aerie granted Deerfield a security interest in an intercompany promissory note and pledged 65% of the voting stock of Aerie Limited. Upon the request of Aerie, Deerfield will release the lien on the intercompany promissory note under certain circumstances.
	At closing, Aerie paid Deerfield a one-time transaction fee of $625,000. In addition, Aerie reimbursed Deerfield in the amount of $250,000 for certain expenses incurred by Deerfield in connection with the transaction. Aerie also incurred $1.3 million of legal and advisory fees in connection with the transaction.
	The 2014 Convertible Notes are convertible at any time at the option of Deerfield, in whole or in part, into shares of common stock, including upon the repayment of the 2014 Convertible Notes at maturity (the “Conversion Option”). However, upon conversion, Deerfield (together with their affiliates) is limited to a 9.985% ownership cap in shares of common stock (the “9.985% Cap”). The 9.985% Cap would remain in place upon any assignment of the 2014 Convertible Notes by Deerfield.
	The initial conversion price is $24.80 per share of common stock (equivalent to an initial conversion rate of 40.32 shares of common stock per $1,000 principal amount of 2014 Convertible Notes), representing a 30% premium over the closing price of the common stock on September 8, 2014. The conversion rate and the corresponding conversion price are subject to adjustment for stock dividends (other than a dividend for which Deerfield would be entitled to participate on an as-converted basis), stock splits, reverse stock splits and reclassifications. In addition, in connection with certain significant corporate transactions, Deerfield, at its option, may (i) require Aerie to prepay all or a portion of the principal amount of the 2014 Convertible Notes, plus accrued and unpaid interest, or (ii) convert all or a portion of the principal amount of the 2014 Convertible Notes into, depending upon the type of transaction, shares of common stock or the right to receive upon consummation of the transaction the consideration Deerfield would have received had Deerfield converted the 2014 Convertible Notes immediately prior to the consummation of the transaction. The 2014 Convertible Notes provide for an increase in the conversion rate if Deerfield elects to convert their 2014 Convertible Notes in connection with a significant corporate transaction. The maximum increase to the initial conversion rate, in connection with a significant corporate transaction, is 12.07 shares of common stock per $1,000 principal amount of 2014 Conversion Notes, which decreases over time and is determined by reference to the price of the common stock prior to the consummation of the significant corporate transaction or the value of the significant corporate transaction.
	The agreement governing the 2014 Convertible Notes contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the incurrence of additional debt and liens on Aerie’s assets. As of March 31, 2015, Aerie was in compliance with the covenants. The agreement governing the 2014 Convertible Notes also provides for certain events of default, including the failure to pay principal and interest when due; inaccuracies in Aerie’s representations and warranties to Deerfield; failure to comply with any of the covenants; Aerie’s insolvency or the occurrence of certain bankruptcy-related events; certain judgments against Aerie; the suspension, cancellation or revocation of governmental authorizations that are reasonably expected to have a material adverse effect on Aerie’s business; the acceleration of a specified amount of indebtedness; and the failure to deliver shares of common stock upon conversion of the 2014 Convertible Notes. If any event of default were to occur, and continue beyond any applicable cure period, the holders of more than 50% of the aggregate principal amount of the then outstanding 2014 Convertible Notes would be permitted to declare the principal and accrued and unpaid interest to be immediately due and payable.
	The Company recorded the 2014 Convertible Notes as long-term debt at face value less debt discounts relating to fees and certain expenses paid to Deerfield in connection with the transaction. The Conversion Option is a derivative that qualifies for an exemption from bifurcation and liability accounting as provided for in ASC Topic 815 “Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASC 815”). Since the Conversion Option is not bifurcated as a derivative pursuant to ASC 815, the Company further evaluated the Conversion Option to determine whether it is considered a beneficial conversion feature (“BCF”). The Company determined that the initial accounting conversion price was greater than the fair value of the common stock at the close of trading on the date of issuance, therefore no BCF existed at inception. However, if Deerfield elects to convert their 2014 Convertible Notes in connection with a significant corporate transaction, the increase to the initial conversion rate may cause a contingent BCF to exist at the time of conversion. The contingent BCF, if any, will be recognized in earnings when the contingency is resolved and will be measured using the fair value of the common stock at the close of trading on the date of issuance and the accounting conversion price as adjusted for such an increase to the initial conversion rate.
	As of March 31, 2015, the Company recognized unamortized debt discounts of $813,000. Debt discounts are amortized using the effective interest method through the earlier of maturity or the conversion of the 2014 Convertible Notes.
	The table below summarizes the carrying value of the 2014 Convertible Notes as of March 31, 2015:
	(in thousands)	31-Mar-15
	Gross proceeds	$	125,000
	Initial value of issuance costs recorded as debt discount	(875		)
	Amortization of debt discount	62
	Carrying value	$	124,187
	For the three months ended March 31, 2015, interest expense related to the 2014 Convertible Notes was $539,000.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The IP Assignment resulted in the recognition of a taxable gain for U.S. federal and state income tax purposes. As of March 31, 2015, the estimated income tax liability was $12.3 million after utilization of net operating loss carry-forwards and current year losses generated through March 31, 2015. Under ASC 810, Consolidation, the income tax expense of $12.3 million for the three months ended March 31, 2015 was recorded as a prepaid asset. The income tax liability and prepaid asset are expected to be substantially reduced by current year losses projected after March 31, 2015. In accordance with ASC 810, Consolidation, the remaining estimated prepaid asset will be amortized over the estimated remaining patent life of the intellectual property subject to the IP Assignment, through approximately 2030.
	As a result of the IP Assignment, the Company reversed approximately $39.3 million of its valuation allowance on certain deferred tax assets, primarily federal and state net operating losses, as of March 31, 2015. Due to the Company’s history of operating losses and lack of available evidence supporting future taxable income, the Company believes that a valuation allowance on its remaining deferred tax assets as of March 31, 2015 remains appropriate.
	In addition, the IP Assignment is subject to complex tax and transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may disagree with the Company’s determinations as to the income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and the Company’s position were not sustained, the Company could be required to pay additional taxes, interest and penalties, which could result in one-time tax charges, higher effective tax rates and reduced cash flows.

Stock_Purchase_Warrants

Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Stock Purchase Warrants	Stock Purchase Warrants
	As of March 31, 2015, the following equity classified warrants were outstanding:
	NUMBER OF	EXERCISE		WARRANT	TYPE OF EQUITY
	UNDERLYING	PRICE PER		EXPIRATION	SECURITY
	SHARES	SHARE		DATE
	2,006	$	5	Mar-16	Common Stock
	75,000	$	5	Feb-19	Common Stock
	75,000	$	5	November 2019	Common Stock
	157,500	$	5	Aug-20	Common Stock
	408,295	$	0.05	December 2019	Common Stock
	The warrants outstanding as of March 31, 2015 are all currently exercisable with weighted-average remaining lives of 4.74 years.

Stockbased_Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation
	Stock-based compensation expense for options granted and restricted stock awards (“RSAs”) is reflected in the consolidated statement of operations as follows:
		THREE MONTHS ENDED MARCH 31,
	(in thousands)	2015			2014
	Research and development	$	511		$	615
	General and administrative	2,230			1,307
	Total	$	2,741		$	1,922
	The estimated fair value of options granted is determined on the date of grant using the Black-Scholes option pricing model. Options granted to non-employees are revalued at each financial reporting period until required service is performed. Compensation expense related to RSAs is based on the market value of the Company’s common stock on the date of grant and is expensed on a straight-line basis (net of estimated forfeitures) over the vesting period.
	As of March 31, 2015, the Company had $26.6 million of unrecognized compensation expense related to options granted under its equity plans. This cost is expected to be recognized over a weighted average period of 2.9 years as of March 31, 2015. The weighted average remaining contractual life on all outstanding options as of March 31, 2015 was 8.4 years.
	As of March 31, 2015, the Company had $2.5 million of unrecognized compensation expense, related to unvested RSAs. This cost is expected to be recognized over a weighted average period of 3.7 years as of March 31, 2015. The weighted average remaining contractual term for RSAs as of March 31, 2015 was 3.7 years.
	Equity Plans
	The Company maintains two equity compensation plans, the 2005 Aerie Pharmaceutical Stock Plan (the “2005 Plan”) and the 2013 Omnibus Incentive Plan (the “2013 Equity Plan”), which was amended and restated as the Aerie Pharmaceuticals, Inc. Amended and Restated Omnibus Incentive Plan (the “Amended and Restated Equity Plan). The 2005 Plan and the Amended and Restated Equity Plan are referred to collectively as the “Plans.”
	On October 30, 2013, the effective date of the 2013 Equity Plan, the 2005 Plan was frozen and no additional awards will be made under the 2005 Plan. Any shares remaining available for future grant under the 2005 Plan were allocated to the 2013 Equity Plan.
	At the 2015 Annual Meeting of Stockholders held on April 10, 2015, the Company’s stockholders approved the adoption of the Amended and Restated Equity Plan and no additional awards will be made under the 2013 Equity Plan. Any shares remaining available under the 2013 Equity Plan were allocated to the Amended and Restated Equity Plan.
	The Amended and Restated Equity Plan provides for the granting of up to 5,729,068 equity awards in respect of common stock of the Company, including equity awards that were available for issuance under the 2013 Equity Plan. The Company granted stock options to employees to purchase 765,800 and 995,600 shares of common stock during the three months March 31, 2015 and 2014, respectively. The Company granted 88,827 and zero RSAs to employees during the three months ended March 31, 2015 and 2014, respectively.
	The following table summarizes the stock option activity under the Plans:
		NUMBER OF		WEIGHTED AVERAGE			AGGREGATE
		SHARES		EXERCISE PRICE			INTRINSIC
							VALUE
							(000’s)
	Options outstanding at December 31, 2014	3,826,459		$	8.39		$	79,792
	Granted	765,800		28.29			—
	Exercised	(14,043	)	0.44			—
	Cancelled	(29,356	)	9.85			—
	Options outstanding at March 31, 2015	4,548,860		$	11.71		$	89,292
	Options exercisable at March 31, 2015	1,721,301		$	5.09		$	45,188
	The following table summarizes the RSA activity under the Plans:
		NUMBER OF		WEIGHTED AVERAGE
		SHARES		FAIR VALUE PER SHARE
	RSAs outstanding at December 31, 2014	103,064		$	2.47
	Granted	88,827		27.5
	Vested	(35,748	)	2.73
	Cancelled	—		—
	RSAs outstanding at March 31, 2015	156,143		$	16.65
	The vesting of the RSAs is time and service based with terms of two to four years. The RSAs are subject to repurchase, such that the Company has the right, but not the obligation, to repurchase unvested shares upon the employee’s termination.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Litigation
	The Company may periodically become subject to legal proceedings and claims arising in connection with its business. Except as set forth below, the Company is not a party to any known litigation, is not aware of any unasserted claims and does not have contingency reserves established for any litigation liabilities.
	A putative securities class action lawsuit captioned Kelley et al. v. Aerie Pharmaceuticals, Inc., et al., Case No. 3:15-cv-03007, was filed against the Company and certain of its officers and directors in the United States District Court for the District of New Jersey on April 29, 2015, on behalf of a purported class of persons and entities who purchased or otherwise acquired the Company’s publicly traded securities between August 6, 2014 and April 23, 2015. The complaint asserts claims under the Securities Exchange Act of 1934 and alleges that the defendants made materially false and misleading statements or omitted allegedly material information during that period related to, among other things, the prospects of the Company’s initial Phase 3 registration trial of RhopressaTM, named “Rocket 1,” and RhopressaTM.
	The Company believes that the claims asserted in the action are without merit and intends to defend the lawsuit vigorously, and the Company expects to incur costs associated with defending the action. In addition, the Company has various insurance policies related to the risks associated with its business, including directors’ and officers’ liability insurance policies. However, there is no assurance that the Company will be successful in its defense of the action, and there is no assurance that the Company’s insurance coverage, which contains a self-insured retention, will be sufficient or that its insurance carriers will cover all claims or litigation costs. At this time, the Company cannot accurately predict the ultimate outcome of this matter. Due to the inherent uncertainties of litigation, the Company cannot reasonably predict the timing or outcomes, or estimate the amount of loss, or range of loss, if any, or their effect, if any, on the Company’s financial statements.
	Contract Service Providers
	In the course of the Company’s normal business operations, it has agreements with contract service providers to assist in the performance of its research and development, clinical research and manufacturing. Substantially all of these contracts are on an as-needed basis.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The Company’s interim consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
Principles of Consolidation	The interim consolidated financial statements include the accounts of Aerie and its wholly-owned subsidiary. All intercompany accounts, transactions and profits have been eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the valuation of stock options and operating expense accruals. Actual results could differ from these estimates.
Investments	Investments
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase. The Company’s investments are comprised of certificates of deposit, commercial paper, corporate bonds and government agency securities that are classified as available-for-sale in accordance with ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year.
	Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in Accumulated other comprehensive gain (loss) on the Company’s consolidated balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of Other income (expense), net (Note 3). There were no realized gains or losses recognized for the three months ended March 31, 2015 or 2014.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to period end. As of March 31, 2015, there were no investments with a fair value that was significantly lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period.
Deferred Financing Costs	Deferred Financing Costs
	Deferred financing costs consist of financing costs incurred by the Company in connection with the closing of Aerie’s 2014 Convertible Notes and are included in Other assets. The Company amortizes deferred financing costs through the earlier of maturity or the conversion of the 2014 Convertible Notes using the effective interest method. Refer to Note 8 for further information regarding the 2014 Convertible Notes.
Fair Value Measurements	Fair Value Measurements
	The Company records certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The fair value of the Company’s financial instruments, including cash and cash equivalents, short-term investments, other current assets, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of these instruments. The carrying amounts of long-term investments represent their estimated fair values. The estimated fair value of Aerie’s 2014 Convertible Notes was $174.0 million and $163.8 million as of March 31, 2015 and December 31, 2014, respectively. As of March 31, 2015 and December 31, 2014, all outstanding warrants are classified as equity and are recorded within additional paid-in capital on the consolidated balance sheets.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU 2015-03, which simplifies the presentation of debt issuance costs. The new standard is effective for the Company for interim and annual periods beginning after December 15, 2015, with early adoption permitted. Upon adoption of ASU 2015-03, the Company will present debt issuance costs as a direct reduction to the debt liability rather than as an asset on its consolidated balance sheets.
	In August 2014, the FASB issued ASU 2014-15, which provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for the Company for the annual period ending after December 15, 2016 and for annual and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on the Company’s consolidated financial statements.
Net Loss per Share Attributable to Common Stock	Net Loss per Share Attributable to Common Stock
	Basic net loss per share attributable to common stock (“Basic EPS”) is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities with the exception of warrants for common stock with a $0.05 exercise price, which are exercisable for nominal consideration and are therefore included in the calculation of the weighted-average number of shares of common stock as common stock equivalents. Diluted net loss per share attributable to common stock (“Diluted EPS”) gives effect to all dilutive potential shares of common stock outstanding during this period. For Diluted EPS, net loss attributable to common stockholders used in calculating Basic EPS is adjusted for certain items related to the dilutive securities.
	For all periods presented, the Company’s potential common stock equivalents have been excluded from the computation of Diluted EPS as their inclusion would have the effect of reducing the net loss per share of common stock. Therefore, the denominator used to calculate Basic EPS and Diluted EPS is the same in all periods presented.
	The Company’s potential common stock equivalents that have been excluded from the computation of Diluted EPS for all periods presented consist of the following:
		THREE MONTHS ENDED MARCH 31,
		2015	2014
	2014 Convertible Notes(1)	5,040,323	—
	Outstanding stock options	4,548,860	4,177,660
	Stock purchase warrants	309,506	309,506
	Unvested restricted common stock awards	156,143	210,317
	-1	Conversion is limited to a 9.985% ownership cap in shares of common stock by the holder. Additionally, the 2014 Convertible Notes provide for an increase in the conversion rate if conversion is elected in connection with a significant corporate transaction. Refer to Note 8 for further information regarding the 2014 Convertible Notes.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Computation of Diluted EPS	The Company’s potential common stock equivalents that have been excluded from the computation of Diluted EPS for all periods presented consist of the following:
		THREE MONTHS ENDED MARCH 31,
		2015	2014
	2014 Convertible Notes(1)	5,040,323	—
	Outstanding stock options	4,548,860	4,177,660
	Stock purchase warrants	309,506	309,506
	Unvested restricted common stock awards	156,143	210,317
	-1	Conversion is limited to a 9.985% ownership cap in shares of common stock by the holder. Additionally, the 2014 Convertible Notes provide for an increase in the conversion rate if conversion is elected in connection with a significant corporate transaction. Refer to Note 8 for further information regarding the 2014 Convertible Notes.

Other_Income_Expense_Net_Table

Other Income (Expense), Net (Tables)	3 Months Ended
	Mar. 31, 2015
Other Income and Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net consists of the following:
		THREE MONTHS ENDED
		MARCH 31,
	(in thousands)	2015			2014
	Interest and amortization expense	$	(617	)	$	—
	Sale of New Jersey state tax benefit	2,898			2,288
	Investment and other income, net	121			23
		$	2,402		$	2,311

Investments_Tables

Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Summary of Cash, Cash Equivalents and Investments	Cash, cash equivalents and investments as of March 31, 2015 included the following:
	(in thousands)	AMORTIZED		GROSS		GROSS			FAIR
		COST		UNREALIZED		UNREALIZED			VALUE
				GAINS		LOSSES
	Cash and cash equivalents:
	Cash and money market accounts	$	113,450	$	—	$	—		$	113,450
	Total cash and cash equivalents	$	113,450	$	—	$	—		$	113,450
	Investments:
	Certificates of deposit (due within 1 year)	$	23,859	$	2	$	(6	)	$	23,855
	Certificates of deposit (due within 2 years)	5,389		2		—			5,391
	Commercial paper (due within 1 year)	5,993		1		(1		)	5,993
	Corporate bonds (due within 1 year)	20,422		—		(37		)	20,385
	Corporate bonds (due within 2 years)	4,198		—		(15		)	4,183
	Government agencies (due within 1 year)	6,056		—		(3		)	6,053
	Total investments	$	65,917	$	5	$	(62	)	$	65,860
	Total cash, cash equivalents, and investments	$	179,367	$	5	$	(62	)	$	179,310

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Summary of Fair Value of Financial Assets and Liabilities that are Measured at Fair Value and the Classification by Level of Input within Fair Value Hierarchy	The following tables summarize the fair value of financial assets and liabilities that are measured at fair value and the classification by level of input within the fair value hierarchy:
		FAIR VALUE MEASUREMENTS AS OF
		31-Mar-15
	(in thousands)	Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
	Cash and money market accounts	$	113,450	$	—	$	—	$	113,450
	Total cash and cash equivalents	$	113,450	$	—	$	—	$	113,450
	Investments:
	Certificates of deposit	$	—	$	29,246	$	—	$	29,246
	Commercial paper	—		5,993		—		5,993
	Corporate bonds	—		24,568		—		24,568
	Government agencies	—		6,053		—		6,053
	Total investments	$	—	$	65,860	$	—	$	65,860
	Total cash, cash equivalents, and investments	$	113,450	$	65,860	$	—	$	179,310
		FAIR VALUE MEASUREMENTS AS OF
		31-Dec-14
	(in thousands)	Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
	Cash and money market accounts	$	84,613	$	—	$	—	$	84,613
	Certificates of deposit	—		472		—		472
	Corporate bonds	—		501		—		501
	Total cash and cash equivalents	$	84,613	$	973	$	—	$	85,586
	Investments:
	Certificates of deposit	$	—	$	30,241	$	—	$	30,241
	Commercial paper	—		5,986		—		5,986
	Corporate bonds	—		30,311		—		30,311
	Government agencies	—		6,076		—		6,076
	Total investments	$	—	$	72,614	$	—	$	72,614
	Total cash, cash equivalents, and investments	$	84,613	$	73,587	$	—	$	158,200

Other_Assets_Net_Tables

Other Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets, net consists of the following:
	(in thousands)	31-Mar-15		DECEMBER 31, 2014
	Deferred financing costs	$	1,378	$	1,479
	Prepaid taxes(1)	12,341		—
	Miscellaneous	153		44
		$	13,872	$	1,523
	-1	Under ASC 810, Consolidation, the income tax expense resulting from the IP Assignment of $12.3 million for the three months ended March 31, 2015 was recorded as a prepaid asset. The prepaid asset is expected to be substantially offset by current year losses and amortized ratably over the estimated remaining patent life of the intellectual property subject to the IP Assignment, through approximately 2030. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Accounts_Payable_Other_Current1

Accounts Payable & Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Summary of Accounts Payable and Other Current Liabilities	Accounts payable and other current liabilities consist of the following:
	(in thousands)	31-Mar-15		DECEMBER 31,
				2014
	Accounts payable	$	3,180	$	2,068
	Accrued expenses and other liabilities:
	Employee benefits and compensation related accruals(1)	940		2,257
	General and administrative related accruals	1,252		731
	Research and development related accruals	4,149		3,280
	Accrued income taxes(2)	12,331		—
		$	21,852	$	8,336
	-1	Comprised of accrued bonus, accrued vacation, and liabilities under the Company’s

Convertible_Notes_Tables

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Summary of Carrying Value of Convertible Notes	The table below summarizes the carrying value of the 2014 Convertible Notes as of March 31, 2015:
	(in thousands)	31-Mar-15
	Gross proceeds	$	125,000
	Initial value of issuance costs recorded as debt discount	(875		)
	Amortization of debt discount	62
	Carrying value	$	124,187

Stock_Purchase_Warrants_Tables

Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Schedule of Equity Classified Warrants Outstanding	As of March 31, 2015, the following equity classified warrants were outstanding:
	NUMBER OF	EXERCISE		WARRANT	TYPE OF EQUITY
	UNDERLYING	PRICE PER		EXPIRATION	SECURITY
	SHARES	SHARE		DATE
	2,006	$	5	Mar-16	Common Stock
	75,000	$	5	Feb-19	Common Stock
	75,000	$	5	November 2019	Common Stock
	157,500	$	5	Aug-20	Common Stock
	408,295	$	0.05	December 2019	Common Stock

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Options Activity	The following table summarizes the stock option activity under the Plans:
		NUMBER OF		WEIGHTED AVERAGE			AGGREGATE
		SHARES		EXERCISE PRICE			INTRINSIC
							VALUE
							(000’s)
	Options outstanding at December 31, 2014	3,826,459		$	8.39		$	79,792
	Granted	765,800		28.29			—
	Exercised	(14,043	)	0.44			—
	Cancelled	(29,356	)	9.85			—
	Options outstanding at March 31, 2015	4,548,860		$	11.71		$	89,292
	Options exercisable at March 31, 2015	1,721,301		$	5.09		$	45,188
Stock-Based Compensation Expense for Options Granted, Restricted Stock and Stock Purchase Rights as Reflected in Statement of Operations	Stock-based compensation expense for options granted and restricted stock awards (“RSAs”) is reflected in the consolidated statement of operations as follows:
		THREE MONTHS ENDED MARCH 31,
	(in thousands)	2015			2014
	Research and development	$	511		$	615
	General and administrative	2,230			1,307
	Total	$	2,741		$	1,922
Restricted Stock and Restricted Stock Units Activity	The following table summarizes the RSA activity under the Plans:
		NUMBER OF		WEIGHTED AVERAGE
		SHARES		FAIR VALUE PER SHARE
	RSAs outstanding at December 31, 2014	103,064		$	2.47
	Granted	88,827		27.5
	Vested	(35,748	)	2.73
	Cancelled	—		—
	RSAs outstanding at March 31, 2015	156,143		$	16.65

The_Company_Additional_Informa

The Company - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2015	Oct. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014
Organization And Nature Of Business [Line Items]
Common stock initial public offering		7,728,000
Public offering price of the shares sold		$10
Net proceeds from initial public offering		$68,300,000
Underwriting discounts and commissions		5,400,000
Payments of stock issuance costs			1,000,000
Expenses for initial public offering		3,600,000
Common stock issued and sold under sales agreement	1,204,248
Proceeds from sale of common stock			35,000,000	0
Convertible notes
Organization And Nature Of Business [Line Items]
Gross proceeds	125,000,000		125,000,000
Net proceeds from issuance of debt			124,100,000
Debt instrument, discounts and certain expenses	875,000		875,000		875,000
Stock Offering Underwriter Over-Allotments Option
Organization And Nature Of Business [Line Items]
Common stock initial public offering		1,008,000
Maximum
Organization And Nature Of Business [Line Items]
Shelf registration statement, aggregate dollar amount			150,000,000
Cantor Fitzgerald and Co. | Common stock | Maximum
Organization And Nature Of Business [Line Items]
Shelf registration statement, aggregate dollar amount			$50,000,000

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Realized investment gains or losses	$0	$0
Investments owned, at fair value	$0
Warrants exercise price	$0.05

Significant_Accounting_Policie4

Significant Accounting Policies - Schedule of Computation of Diluted EPS (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ownership cap in shares of common stock	9.99%
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the computation of diluted net loss per share	5,040,323
Ownership cap in shares of common stock	9.99%
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the computation of diluted net loss per share	4,548,860	4,177,660
Stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the computation of diluted net loss per share	309,506	309,506
Unvested restricted common stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the computation of diluted net loss per share	156,143	210,317

Other_Income_Expense_Net_Sched

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Other Income and Expenses [Abstract]
Interest expense	($617)	$0
Sale of New Jersey state tax benefit	2,898	2,288
Investment and other income, net	121	23
Other income (expense), net	$2,402	$2,311

Investments_Summary_of_Cash_Ca

Investments - Summary of Cash, Cash Equivalents and Investments (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investment Holdings [Line Items]
Amortized Cost	$113,450	$85,586	$35,843	$69,649
Fair Value	113,450	85,586
Amortized Cost	179,367	158,307
Gross Unrealized Gains	5	2
Gross Unrealized Losses	-62	-109
Fair Value	179,310	158,200
Cash and money market accounts
Investment Holdings [Line Items]
Amortized Cost	113,450	84,613
Fair Value	113,450	84,613
Certificates of deposit
Investment Holdings [Line Items]
Amortized Cost		472
Fair Value		472
Corporate bonds
Investment Holdings [Line Items]
Amortized Cost		501
Fair Value		501
Certificates of deposit (due within 1 year)
Investment Holdings [Line Items]
Amortized Cost	23,859	25,823
Gross Unrealized Gains	2	0
Gross Unrealized Losses	-6	-9
Fair Value	23,855	25,814
Certificates of Deposit, Due Within Two Years [Member]
Investment Holdings [Line Items]
Amortized Cost	5,389	4,429
Gross Unrealized Gains	2	1
Gross Unrealized Losses	0	-3
Fair Value	5,391	4,427
Corporate bonds (due within 1 year)
Investment Holdings [Line Items]
Amortized Cost	20,422	16,487
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-37	-24
Fair Value	20,385	16,463
Corporate Bonds, Due within 2 years [Member]
Investment Holdings [Line Items]
Amortized Cost	4,198	13,912
Gross Unrealized Gains	0
Gross Unrealized Losses	-15	-64
Fair Value	4,183	13,848
US Government Corporations and Agencies Securities [Member]
Investment Holdings [Line Items]
Amortized Cost	6,056	6,082
Gross Unrealized Gains	0
Gross Unrealized Losses	-3	-6
Fair Value	6,053	6,076
Total investments
Investment Holdings [Line Items]
Amortized Cost	65,917	72,721
Gross Unrealized Gains	5	2
Gross Unrealized Losses	-62	-109
Fair Value	65,860	72,614
Commercial paper
Investment Holdings [Line Items]
Amortized Cost	5,993	5,988
Gross Unrealized Gains	1	1
Gross Unrealized Losses	-1	-3
Fair Value	$5,993	$5,986

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities that are Measured at Fair Value and the Classification by Level of Input within Fair Value Hierarchy (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents	$113,450	$85,586
Total investments	65,860	72,614
Total cash, cash equivalents, and investments	179,310	158,200
Cash and money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents	113,450	84,613
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		472
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		501
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents	113,450	84,613
Total investments	0
Total cash, cash equivalents, and investments	113,450	84,613
Level 1 | Cash and money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents	113,450	84,613
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		973
Total investments	65,860	72,614
Total cash, cash equivalents, and investments	65,860	73,587
Level 2 | Cash and money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		0
Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		472
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash and cash equivalents		501
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	29,246	30,241
Certificates of deposit | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0
Certificates of deposit | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	29,246	30,241
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	5,993	5,986
Commercial paper | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0
Commercial paper | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	5,993	5,986
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	24,568	30,311
Corporate bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0
Corporate bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	24,568	30,311
Government agencies
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	6,053	6,076
Government agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0
Government agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	$6,053	$6,076

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Debt Instrument Fair Value Carrying Value [Abstract]
Long-term debt, fair value	$174	$163.80

Other_Assets_Net_Schedule_of_O

Other Assets, Net -Schedule of Other Assets (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred financing costs	$1,378		$1,479
Prepaid taxes	12,341	[1]	0	[1]
Miscellaneous	153		44
Other assets	$13,872		$1,523
[1]	Under ASC 810, Consolidation, the income tax expense resulting from the IP Assignment of $12.3 million for the three months ended March 31, 2015 was recorded as a prepaid asset. The prepaid asset is expected to be substantially offset by current year losses and amortized ratably over the estimated remaining patent life of the intellectual property subject to the IP Assignment, through approximately 2030. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Accounts_Payable_Other_Current2

Accounts Payable & Other Current Liabilities - Summary of Accounts Payable and Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accounts payable	$3,180		$2,068
Accrued expenses and other liabilities:
Employee benefits and compensation related accruals	940	[1]	2,257	[1]
General and administrative related accruals	1,252		731
Research and development related accruals	4,149		3,280
Accrued income taxes	12,331	[2]	0	[2]
Accounts payable and other accrued liabilities	$21,852		$8,336
[1]	Comprised of accrued bonus, accrued vacation, and liabilities under the Company’s employee stock purchase plan.
[2]	Accrued income taxes are the result of the tax gain from the IP Assignment and are expected to be substantially offset by current year losses. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Sep. 08, 2014	Mar. 31, 2015	Sep. 08, 2014
Debt Instrument [Line Items]
Debt instrument, convertible, ownership cap in shares of common stock		9.99%
Convertible notes
Debt Instrument [Line Items]
Debt instrument, interest rate percentage		1.75%
Debt instrument, interest rate description		payable quarterly in arrears on the first business day of each January, April, July and October.
Debt instrument, maturity description		seventh anniversary from the date of issuance
Debt instrument, convertible, stock price trigger		$30
Debt instrument, convertible, threshold trading days		30 days
Debt instrument, convertible, terms of security		The Convertible Notes constitute a senior secured obligation of the Company, collateralized by a first priority security interest in substantially all of the assets of the Company. The Convertible Notes provide that, upon the request of the Company, Deerfield will release all of the liens on the collateral if both of the following occur: (i) beginning one month after U.S. Food and Drug Administration approval of either Rhopressa™ or Roclatan™, shares of the Company’s common stock have traded at a price above $30 per share (subject to adjustment for any subdivision or combination of outstanding common stock) for 30 consecutive trading days, and (ii) the Company is prepared to close a financing that will be secured by a lien on the Company’s assets, subject only to the release of the lien on the Company’s assets by Deerfield.
Debt instrument, transaction fee		$625,000
Reimbursed expenses incurred by Deerfield in connection with transaction		250,000
Legal and advisory fees		1,300,000
Debt instrument, convertible, ownership cap in shares of common stock		9.99%
Debt instrument, convertible, initial conversion price per share	$24.80		$24.80
Debt instrument, convertible, common stock conversion rate per $1,000 principal amount	40.32
Debt instrument, convertible, conversion premium percentage	30.00%		30.00%
Debt instrument, convertible, maximum increase to the initial conversion rate per $1,000 principal amount		12.07
Debt instrument, convertible, ownership percentage threshold necessary to declare principal and accrued interest payable and due in the event of default		50.00%
Unamortized debt discounts		813,000
Interest expense related to Convertible Notes		$539,000

Convertible_Notes_Summary_of_C

Convertible Notes - Summary of Carrying Value of Convertible Notes (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Convertible notes, net of discounts	$124,187	$124,156
Convertible notes
Debt Instrument [Line Items]
Gross proceeds	125,000
Initial value of issuance costs recorded as debt discount	-875		-875
Amortization of debt discount	62
Convertible notes, net of discounts	$124,187

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Income Taxes [Line Items]
Income tax liability	$12,331,000	[1]	$0	[1]
Net Operating Losses Related to IP Assignment
Income Taxes [Line Items]
Increase (decrease) in valuation allowance	($39,300,000)
[1]	Accrued income taxes are the result of the tax gain from the IP Assignment and are expected to be substantially offset by current year losses. Refer to Note 9 for a description of the tax impact of the IP Assignment.

Stock_Purchase_Warrants_Schedu

Stock Purchase Warrants - Schedule of Equity Classified Warrants Outstanding (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
EXERCISE PRICE PER SHARE	$0.05
March 2016 | Common stock
Class of Warrant or Right [Line Items]
NUMBER OF UNDERLYING SHARES	2,006	2,006
EXERCISE PRICE PER SHARE	$5	$5
February 2019 | Common stock
Class of Warrant or Right [Line Items]
NUMBER OF UNDERLYING SHARES	75,000	75,000
EXERCISE PRICE PER SHARE	$5	$5
November 2019 | Common stock
Class of Warrant or Right [Line Items]
NUMBER OF UNDERLYING SHARES	75,000	75,000
EXERCISE PRICE PER SHARE	$5	$5
August 2020 | Common stock
Class of Warrant or Right [Line Items]
NUMBER OF UNDERLYING SHARES	157,500	157,500
EXERCISE PRICE PER SHARE	$5	$5
December 2019 | Common stock
Class of Warrant or Right [Line Items]
NUMBER OF UNDERLYING SHARES	408,295	408,295
EXERCISE PRICE PER SHARE	$0.05	$0.05

Stock_Purchase_Warrants_Additi

Stock Purchase Warrants - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Weighted-average remaining lives	4 years 8 months 27 days

Stockbased_Compensation_Additi

Stock-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014
	Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity compensation plans	2
Stock-based awards, shares granted	765,800
Restricted stock, shares issued	88,827	0
Stock-based compensation expense	$2,741	$1,922
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,230	1,307
2013 Omnibus incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity awards	5,729,068
Stock-based awards, shares granted			765,800	995,600
2005 Aerie Pharmaceutical stock plan and 2013 omnibus incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	26,600
Compensation cost, weighted average recognition period	2 years 10 months 24 days
Options outstanding, weighted average remaining contractual life	8 years 4 months 24 days
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$2,524
Restricted stock, shares issued	88,827
Restricted stock, unvested shares	156,143				103,064
Restricted stock awards, weighted average remaining contractual term	3 years 8 months 12 days
Restricted stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards, vesting period	2 years
Restricted stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards, vesting period	4 years

Stockbased_Compensation_Schedu

Stock-based Compensation - Schedule of Stock Options Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding at December 31, 2013, Number of Shares	3,826,459
Granted, Number of Shares	765,800
Exercised, Number of Shares	-14,043
Cancelled, Number of Shares	-29,356
Options outstanding at September 30, 2014, Number of Shares	4,548,860
Options exercisable at September 30, 2014, Number of Shares	1,721,301
Options outstanding at December 31, 2013, Weighted Average Exercise Price	$8.39
Granted, Weighted Average Exercise Price	$28.29
Exercised, Weighted Average Exercise Price	$0.44
Cancelled, Weighted Average Exercise Price	$9.85
Options outstanding at September 30, 2014, Weighted Average Exercise Price	$11.71
Options exercisable at September 30, 2014, Weighted Average Exercise Price	$5.09
Options outstanding at December 31, 2013, Aggregate Intrinsic Value	$79,792
Options outstanding at September 30, 2014, Aggregate Intrinsic Value	89,292
Options exercisable at September 30, 2014, Aggregate Intrinsic Value	$45,188

Stockbased_Compensation_StockB

Stock-based Compensation - Stock-Based Compensation Expense for Options Granted, Restricted Stock and Stock Purchase Rights as Reflected in Statement of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$2,741	$1,922
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	511	615
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$2,230	$1,307

Stockbased_Compensation_Restri

Stock-based Compensation - Restricted Stock and Restricted Stock Units Activity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based compensation, restricted stock, other than options, grants in period	88,827	0
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based compensation, restricted stock, other than options, beginning balance	103,064
Share-based compensation, restricted stock, other than options, grants in period	88,827
Share-based compensation, restricted stock, other than options, vested in period	-35,748
Share-based compensation, restricted stock, other than options, forfeited in period	0
Share-based compensation, restricted stock, other than options, ending balance	156,143
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based compensation, restricted stock, weighted average, beginning balance	2.47
Share-based compensation, restricted stock, weighted average, granted in period	27.5
Share-based compensation, restricted stock, weighted average, vested in period	2.73
Share-based compensation, restricted stock, weighted average, forfeitures in period	0
Share-based compensation, restricted stock, weighted average, ending balance	16.65

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingency reserves for litigation	$0